DE602004017777D1 - Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit - Google Patents

Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit

Info

Publication number
DE602004017777D1
DE602004017777D1 DE602004017777T DE602004017777T DE602004017777D1 DE 602004017777 D1 DE602004017777 D1 DE 602004017777D1 DE 602004017777 T DE602004017777 T DE 602004017777T DE 602004017777 T DE602004017777 T DE 602004017777T DE 602004017777 D1 DE602004017777 D1 DE 602004017777D1
Authority
DE
Germany
Prior art keywords
treatment
indolhydroxyethylamine
tricyclic
derivatives
alzheimer disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004017777T
Other languages
German (de)
English (en)
Inventor
Sally Redshaw
Emmanuel Hubert Demont
Daryl Simon Walter
David R Vesey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602004017777D1 publication Critical patent/DE602004017777D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004017777T 2003-12-12 2004-12-09 Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit Expired - Fee Related DE602004017777D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds
PCT/EP2004/014076 WO2005058915A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DE602004017777D1 true DE602004017777D1 (de) 2008-12-24

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017777T Expired - Fee Related DE602004017777D1 (de) 2003-12-12 2004-12-09 Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit

Country Status (17)

Country Link
US (1) US20070073060A1 (https=)
EP (1) EP1692143B1 (https=)
JP (1) JP2007513913A (https=)
KR (1) KR20060121164A (https=)
CN (1) CN1914214A (https=)
AT (1) ATE414090T1 (https=)
AU (1) AU2004299231A1 (https=)
BR (1) BRPI0417476A (https=)
CA (1) CA2549072A1 (https=)
DE (1) DE602004017777D1 (https=)
GB (1) GB0328900D0 (https=)
IL (1) IL175819A0 (https=)
IS (1) IS8521A (https=)
MA (1) MA28241A1 (https=)
NO (1) NO20063137L (https=)
RU (1) RU2006124863A (https=)
WO (1) WO2005058915A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
PT2185561E (pt) * 2007-07-27 2011-09-07 Sanofi Aventis Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
EP2310019A4 (en) * 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN104768949A (zh) * 2012-08-24 2015-07-08 特温蒂斯公司 苯并呋咱抗淀粉样蛋白化合物和方法
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
IL175819A0 (en) 2006-10-05
KR20060121164A (ko) 2006-11-28
BRPI0417476A (pt) 2007-05-08
AU2004299231A1 (en) 2005-06-30
EP1692143A1 (en) 2006-08-23
IS8521A (is) 2006-06-26
CA2549072A1 (en) 2005-06-30
EP1692143B1 (en) 2008-11-12
NO20063137L (no) 2006-08-31
RU2006124863A (ru) 2008-01-20
WO2005058915A1 (en) 2005-06-30
ATE414090T1 (de) 2008-11-15
US20070073060A1 (en) 2007-03-29
CN1914214A (zh) 2007-02-14
JP2007513913A (ja) 2007-05-31
GB0328900D0 (en) 2004-01-14
MA28241A1 (fr) 2006-10-02

Similar Documents

Publication Publication Date Title
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
ATE414090T1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
WO2005090296A3 (en) N-substituted benzene sulfonamides
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
ATE469146T1 (de) Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee